Dr. Loven is Partner at Nextech, a leading, global investment firm that focuses on early, private-stage cancer companies. A scientific entrepreneur and biotech venture capitalist, Dr. Loven has extensive experience in creating, launching, and building early stage therapeutic companies in the US and most recently led the $57M launch of Relay Therapeutics from Third Rock Ventures, joining the company full time to lead corporate strategy, business development, and operations. Prior to Relay, Dr. Loven was a Scientific Co-Founder of Syros Pharmaceuticals (NASDAQ: SYRS) which was founded on his co-discoveries in gene regulation and was involved from its inception to advancing the first clinical candidate, growing the company to 30+ employees through to the initial public offering in July 2016. Jakob holds a BA in Biomedical Sciences from the Anglia Ruskin University of Cambridge, earned his Ph.D. in Medical Sciences from Karolinska Institutet, and conducted his postdoctoral fellowship at the Whitehead Institute for Biomedical Research.